Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 2Glioblastoma 2Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

Pemetrexed 18Bevacizumab 9Spinal Puncture 7Radiotherapy 7Specimen Handling 5Methotrexate 5Magnetic Resonance Spectroscopy 5osimertinib 4aflutinib 4Trastuzumab 3Topotecan 3Temozolomide 3Dexamethasone 3trastuzumab deruxtecan 2pembrolizumab 2merphos 2lorlatinib 2Vitamin B 12 2Rituximab 2Radiotherapy, Intensity-Modulated 2Folic Acid 2Drug Therapy 2Cytarabine 2Cyclophosphamide 2tucatinib 1toripalimab 1sintilimab 1sacituzumab govitecan 1pertuzumab 1peginterferon alfa-2b 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Meningeal Carcinomatosis × azeliragon × Clear all
NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡